Shares of Amgen Inc. AMGN rallied 1.13% to $290.33 Friday, on what proved to be an all-around great trading session for the ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Patent claims reciting compounds where at least one group of a compound genus is defined by its function are common. For ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

Fifth Third Wealth Advisors increased its stake in Amgen by 36.3% in Q1, now holding shares worth $1.93 million.

First Hawaiian Bank recently reduced its Amgen holdings by 39.2%, unloading over 2,100 shares during the first quarter. The ...

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen’s bone cancer drug XGEVA, used to ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...